-+ 0.00%
-+ 0.00%
-+ 0.00%

Phio Pharmaceuticals reports PH-762 is well tolerated in Phase 1b skin cancer trial

PUBT·11/09/2026 12:07:32
Listen to the news
Phio Pharmaceuticals reports PH-762 is well tolerated in Phase 1b skin cancer trial
  • Phio Pharmaceuticals presented final Phase 1b results for PH-762 at the American Society for Dermatologic Surgery meeting held November 5-8, 2026.
  • Findings suggested PH-762 was well tolerated, with potential to spare tissue when used before surgery for cutaneous squamous cell carcinoma.
  • Further studies are needed to assess safety and efficacy; a Phase 2b trial is planned for the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611090700NEWSFILECNPR____20261109_323016_1) on November 09, 2026, and is solely responsible for the information contained therein.